All In Biotech

Drug Trial Radar · NCT05142553

Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.

A Phase IIb, Double-Blind, Randomised, Active-Controlled, Multicentre, Non-Inferiority Trial Followed by a Phase III, Single-Arm, Open-Label Trial to Assess Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Fusion Dimer Candidate (PHH-1V) Against SARS-CoV-2 in Adults Fully Vaccinated Against COVID-19 Followed by an Extension Period to Study a Fourth Dose Administration of PHH-1V.

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,164 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,164

Actual

Start

Nov 15, 2021

Primary completion

May 29, 2023

Study completion May 29, 2023

Sponsor

Lead sponsor
Hipra Scientific, S.L.UIndustry
Sponsor type
Industry
First posted
Dec 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase IIb clinical study aims to compare the immunogenicity and safety of a booster dose of recombinant protein RBD fusion dimer vaccine as a heterologous booster (to subjects who have received the second dose of the Pfizer-BioNTech (Comirnaty) COVID-19 vaccine at least 182 days prior to the booster dose in this study) versus a homologous booster (subjects who received the second dose of the Comirnaty COVID-19 vaccine at least 182 days prior to the booster dose in this study) will receive a third dose of the Comirnaty vaccine). The extension part of the study aims to compare the immunogenicity and safety of a fourth dose of PHH-1V in subjects with a primovaccination with Pfizer-BioNTech (Comirnaty) COVID-19 vaccine plus either a booster dose of Comirnaty or PHH-1V versus those with three vaccinations of Comirnaty.

Conditions

  • SARS-CoV 2 Infection

Interventions

  • COVID-19 Vaccine HIPRABiological

    Subjects will receive one injection of COVID-19 Vaccine HIPRA

  • Cominarty (Pfizer-BioNtech)Biological

    Subjects will receive one injection of Cominarty Vaccine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Changes of the immunogenicity against WuhanTime frame: 14 days
  2. Safety and tolerability of PHH-1V as third or fourth doseTime frame: 7 days
  3. Safety and tolerability of PHH-1V as third or fourth doseTime frame: 28 days
  4. Safety and tolerability of PHH-1V as third or fourth doseTime frame: 364 days
  5. Safety and tolerability of PHH-1V as third or fourth doseTime frame: Days 14, 28, 182, and 364
  6. Part B: Changes of the immunogenicity against Omicron BA.1Time frame: Day 14

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital Clinic de Barcelona

    Barcelona, Barcelona, Spain

  • Hospital Germans Trias I Pujol

    Badalona, BARCELONA, Spain

  • Hospital Vall Hebron

    Barcelona, BARCELONA, Spain

  • Hospital Universitari Dr. Josep Trueta

    Girona, Girona, Spain

  • Hospital Gregorio Marañón

    Madrid, Madrid, Spain

  • Hospital Universitario La Paz

    Madrid, Madrid, Spain

  • Hospital Principe de Asturias

    Meco, Madrid, Spain

  • Hospital Regional Universitario de Málaga

    Málaga, Málaga, Spain

  • Hospital Clínico de Valencia

    Valencia, Valencia, Spain

  • Hospital de Cruces

    Barakaldo, VIZCAYA, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.